NovoCure Statistics
Total Valuation
NovoCure has a market cap or net worth of $3.33 billion. The enterprise value is $3.05 billion.
Important Dates
The last earnings date was Wednesday, October 30, 2024, before market open.
Earnings Date | Oct 30, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
NovoCure has 108.20 million shares outstanding. The number of shares has increased by 1.49% in one year.
Current Share Class | 108.20M |
Shares Outstanding | 108.20M |
Shares Change (YoY) | +1.49% |
Shares Change (QoQ) | +0.51% |
Owned by Insiders (%) | 8.95% |
Owned by Institutions (%) | 86.35% |
Float | 98.51M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 5.73 |
Forward PS | 5.23 |
PB Ratio | 9.23 |
P/TBV Ratio | 9.24 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 5.28 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.49, with a Debt / Equity ratio of 1.87.
Current Ratio | 1.49 |
Quick Ratio | 1.43 |
Debt / Equity | 1.87 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -17.55 |
Financial Efficiency
Return on equity (ROE) is -39.70% and return on invested capital (ROIC) is -9.29%.
Return on Equity (ROE) | -39.70% |
Return on Assets (ROA) | -7.93% |
Return on Capital (ROIC) | -9.29% |
Revenue Per Employee | $397,617 |
Profits Per Employee | -$103,086 |
Employee Count | 1,453 |
Asset Turnover | 0.49 |
Inventory Turnover | 3.57 |
Taxes
In the past 12 months, NovoCure has paid $35.29 million in taxes.
Income Tax | 35.29M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +125.97% in the last 52 weeks. The beta is 0.76, so NovoCure's price volatility has been lower than the market average.
Beta (5Y) | 0.76 |
52-Week Price Change | +125.97% |
50-Day Moving Average | 21.04 |
200-Day Moving Average | 18.27 |
Relative Strength Index (RSI) | 64.24 |
Average Volume (20 Days) | 1,948,257 |
Short Selling Information
The latest short interest is 5.63 million, so 5.21% of the outstanding shares have been sold short.
Short Interest | 5.63M |
Short Previous Month | 5.67M |
Short % of Shares Out | 5.21% |
Short % of Float | 5.72% |
Short Ratio (days to cover) | 6.23 |
Income Statement
In the last 12 months, NovoCure had revenue of $577.74 million and -$149.78 million in losses. Loss per share was -$1.39.
Revenue | 577.74M |
Gross Profit | 442.26M |
Operating Income | -150.19M |
Pretax Income | -141.13M |
Net Income | -149.78M |
EBITDA | -140.61M |
EBIT | -150.19M |
Loss Per Share | -$1.39 |
Full Income Statement Balance Sheet
The company has $959.90 million in cash and $675.63 million in debt, giving a net cash position of $284.27 million or $2.63 per share.
Cash & Cash Equivalents | 959.90M |
Total Debt | 675.63M |
Net Cash | 284.27M |
Net Cash Per Share | $2.63 |
Equity (Book Value) | 360.78M |
Book Value Per Share | 3.34 |
Working Capital | 360.27M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$37.48 million and capital expenditures -$40.73 million, giving a free cash flow of -$78.21 million.
Operating Cash Flow | -37.48M |
Capital Expenditures | -40.73M |
Free Cash Flow | -78.21M |
FCF Per Share | -$0.72 |
Full Cash Flow Statement Margins
Gross margin is 76.55%, with operating and profit margins of -26.00% and -25.93%.
Gross Margin | 76.55% |
Operating Margin | -26.00% |
Pretax Margin | -19.82% |
Profit Margin | -25.93% |
EBITDA Margin | -24.34% |
EBIT Margin | -26.00% |
FCF Margin | n/a |
Dividends & Yields
NovoCure does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -1.49% |
Shareholder Yield | -1.49% |
Earnings Yield | -4.49% |
FCF Yield | -2.35% |
Dividend Details Analyst Forecast
The average price target for NovoCure is $33.40, which is 8.44% higher than the current price. The consensus rating is "Buy".
Price Target | $33.40 |
Price Target Difference | 8.44% |
Analyst Consensus | Buy |
Analyst Count | 5 |
Revenue Growth Forecast (5Y) | 20.20% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
NovoCure has an Altman Z-Score of 0.37 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 0.37 |
Piotroski F-Score | 4 |